EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reconsidering the Mechanism of Proton Pump Inhibitor‐Associated Fundic Gland Polyps: Absence of Re‐enlargement during Potassium‐Competitive Acid Blocker Therapy

Yoshitsugu Misumi, Tatsuyuki Marumo, Shinichi Ban, Kouichi Nonaka

DEN Open · 2027-04 · 7 (1)

DOI: 10.1002/deo2.70463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift DEN Open, online erschienen am 01.11.2026. Verfasst von Yoshitsugu Misumi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Endoscopy Tokyo Women's Medical University Hospital Tokyo Japan. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fundic gland polyps (FGPs) may enlarge during long‐term proton pump inhibitor (PPI) therapy, potentially in association with acid suppression and hypergastrinemia. Potassium‐competitive acid blockers (PCABs) provide potent and sustained acid suppression and may induce comparable or greater elevations in serum gastrin levels than PPIs. We report a case of FGPs in which regression was documented after changes in acid‐suppressive therapy, with no subsequent re‐enlargement during long‐term use of PCABs. A woman in her 60s with gastroesophageal reflux disease developed progressive enlargement of FGPs during 7 years of rabeprazole therapy. Rabeprazole was discontinued because of marked redness of the enlarged FGPs and concern for possible bleeding and was replaced with an H2‐receptor antagonist. After reintroduction of rabeprazole, treatment was switched to a PCAB because of insufficient symptom control. Four months after PCAB initiation, esophagogastroduodenoscopy demonstrated marked regression of the FGPs, with no subsequent re‐enlargement during continued PCAB therapy. Serum gastrin levels were elevated at both measurements during PCAB use (491.9 and 753.7 pg/mL). Histological examination revealed similar fundic gland changes characteristic of FGPs in both a residual polyp and the endoscopically non‐polypoid background mucosa, without dysplasia. Because the exact timing of FGP regression could not be determined, the regression observed 4 months after vonoprazan initiation cannot be solely attributed to vonoprazan therapy and may have occurred, at least in part, during the preceding period of PPI discontinuation. Nevertheless, no subsequent re‐enlargement was observed during long‐term vonoprazan therapy. Clinical Trial Registration: Clinical trial registration was not applicable because this was a single case report.

Schlagwörter

Stichwörter der Autor:innen

esophagogastroduodenoscopyfundic gland polypsgastrinpotassium‐competitive acid blockersproton pump inhibitors

Autor:innen und Institutionen

  • Department of Digestive Endoscopy Tokyo Women's Medical University Hospital Tokyo Japan.
  • Department of Gastroenterology Ina Hospital Saitama Japan.
  • Department of Pathology Dokkyo Medical University Saitama Medical Center Saitama Japan.

Zitieren

APA

Misumi, Y., Marumo, T., Ban, S., & Nonaka, K. (2027). Reconsidering the Mechanism of Proton Pump Inhibitor‐Associated Fundic Gland Polyps: Absence of Re‐enlargement during Potassium‐Competitive Acid Blocker Therapy. DEN Open, 7(1). https://doi.org/10.1002/deo2.70463

Vancouver

Misumi Y, Marumo T, Ban S, Nonaka K. Reconsidering the Mechanism of Proton Pump Inhibitor‐Associated Fundic Gland Polyps: Absence of Re‐enlargement during Potassium‐Competitive Acid Blocker Therapy. DEN Open. 2027;7(1). doi:10.1002/deo2.70463

BibTeX
@article{Misumi2027,
  author = {Misumi, Yoshitsugu and Marumo, Tatsuyuki and Ban, Shinichi and Nonaka, Kouichi},
  title = {Reconsidering the Mechanism of Proton Pump Inhibitor‐Associated Fundic Gland Polyps: Absence of Re‐enlargement during Potassium‐Competitive Acid Blocker Therapy},
  journal = {DEN Open},
  year = {2027},
  volume = {7},
  number = {1},
  doi = {10.1002/deo2.70463}
}
Kostenlos starten →